2013; McLendon et al. 2008; Verhaak et al. 2010). An intragenic rearrangement of EGFR, called EGFRvIII, is observed in 50% of EGFR‐positive cases and renders the receptor ligand‐independent and constitutively activated (An et al. 2018). Despite EGFR's proven driver mutation function in GBM (Zhu et al. 2009; Jun et al. 2012; Acquaviva et al. 2011), EGFR inhibition has remained ineffective in clinical settings (Lin et al. 2022). Here, EGFR is linked to glioblastoma.